+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biologics Outsourcing Market by Product, by Type, by Sources and for Applications: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • ID: 4853042
  • Report
  • February 2018
  • Region: Global
  • 130 pages
  • Zion Market Research
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now

Report Brief

  • The report covers forecast and analysis for the biologics outsourcing market on a global and regional level
  • The report includes the positive and the negative factors that are influencing the growth of the market
  • Detailed information about the market opportunities are discussed
  • The key target audience for the market has been determined in the report
  • The revenue generated by the prominent industry players has been analyzed in the report
  • The market numbers have been calculated using top-down and the bottom-up approaches 
  • The biologics outsourcing market has been analyzed using Porter’s Five Forces Analysis
  • The market is segmented on the basis of product, sources, type, and applications, which in turn bifurcated on regional level as well
  • All the segments have been evaluated based on the present and the future trends
  • The report deals with the in-depth quantitative and qualitative analyses of the Biologics Outsourcing market
  • The report includes the detailed company profiles of the prominent market players

Market Summary

Overview

In global biologics outsourcing market, the biologics are expected to be a significant area of growth, however, they are starting from a lower base and there is a greater bias against outsourcing biologics production. Outsourcing is increasing as a percentage of the whole manufacturing capacity due to relatively more of new product manufacturing is outsourced and facilities with products that become generic are non-core and are being divested. Increasing investments in the research & development of biologics are significantly propelling the outsourcing market among the big as well as small pharmaceutical and biotechnological industries.

Value

The global biologics outsourcing market was valued at around USD 8,420.0 million in the year 2016 and it is expected to reach approximately USD 32,000.0 million by 2024. The global biologics outsourcing market is expected to grow at a CAGR of over 18.0% between 2017 and 2024.

Drivers and Restraints

The major factor driving the growth of biologics outsourcing market is the increasing investments in research & development of biologic drugs. Because of the facilities with products that become generic are non-core and are being divested and relatively more of new product manufacturing is outsourced the outsourcing is increasing as a percentage of the whole manufacturing capacity. Using a third-party manufacturer can act as an additional site in a multiple site supply strategy, provide backup capacity and increased supply security. In addition, biologics capacity has been built up by CMOs to enable more production to be externalized which will ultimately propel the biologics outsourcing market.

Development of Biologics required high capital and time investment which is expected to arrest the growth of this industry in the years to come.

Segmentation

Antibody product segment is accounted for the largest market share in 2017 and expected to dominate the market by the end of forecast period. The antibody segment is further sub-segmented into a monoclonal antibody, bi-specific antibody, and antibody drug conjugates. From which monoclonal antibodies accounted for the largest market share. Increasing approval for an orphan indication has climbed to more than 50% in the current decade will propel the segment during the forecast period.

Microbial source segment dominates the mammalian and other sources such as Transgenic Models, Avian, and etc. number of products discovered and manufactured by microbial sources will keep the segment dominance throughout the forecast period.

The kits & reagents sector is dominating the biologics outsourcing market. Owing to the increasing use of different kits & reagents in numerous clinical trials and other microbiological activities. 

Considering the applications of global biologics market, vaccine & therapeutics development segment is anticipated to hold the largest market share. The factors such as increasing awareness about disease prevention by vaccination and rising investments in R&D of vaccine segment will boost the segment in near future

North America is the largest market for pharmaceutical/biopharmaceutical research, conducting more than three-quarters of the world’s research and development and holding the IP rights for most of the world’s new drug products, hence it the dominating the biologics outsourcing market globally. The Asia Pacific is anticipated to be the most lucrative region in the global biologics outsourcing market. Owing to the increasing pharmaceutical sector in the region and rising government initiatives for the healthcare industry. 

Industry Players

The report includes detailed profiles of the prominent market players that are trending in the market. The list of the players that are compiled in the report is Boehringer Ingelheim GmbH, Catalent, Inc., GenScript, Innovent Biologics, Inc., Syngene, Shanghai Medicilon inc., GL Biochem Corporation Ltd., GVK Biosciences Private Limited, Horizon Discovery Group plc. Innovent Biologics, Inc., Selexis SA, Lonza, Abzena Plc, Adimab LLC., and much more.

The prominent market players maintain the competitive edge in the global market by making investments in the mergers and acquisitions and by increasing their product portfolio. In October 2017, Boehringer Ingelheim and Siamab Therapeutics, Inc. announced that they have entered into a strategic discovery collaboration with the goal of developing anti-cancer therapeutics targeting tumor-associated carbohydrate antigens (TACAs). 

Note: Product cover images may vary from those shown
2 of 2
  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global biologics outsourcing market, 2016 – 2024 (USD Million)
    • 2.2. Global biologics outsourcing market: Snapshot
  • Chapter 3. Biologics outsourcing– Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global biologics outsourcing market drivers: Impact analysis
      • 3.2.2. Increasing R&D spending on biologics drugs
      • 3.2.3. Enormous cost & time-saving advantages
    • 3.3. Market Restraints
      • 3.3.1. Global biologics outsourcing market restraints: Impact analysis
      • 3.3.2. High technical requirement
    • 3.4. Opportunities
      • 3.4.1. Leverage outside technology
    • 3.5. Porter’s five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat of new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by product segment
      • 3.6.2. Market attractiveness analysis, by type segment
      • 3.6.3. Market attractiveness analysis, by source segment
      • 3.6.4. Market attractiveness analysis, by application segment
      • 3.6.5. Market attractiveness analysis, by regional segment
  • Chapter 4. Global Biologics outsourcing Market – Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global biologics outsourcing market: company market share, 2016
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Therapy Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Therapy and Regional Expansion
    • 4.3. Price Trend Analysis
    • 4.4. Technology Portfolio
  • Chapter 5. Global Biologics outsourcing Market – Product Segment Analysis
    • 5.1. Global biologics outsourcing market: Product type overview
      • 5.1.1. Global biologics outsourcing market revenue share, by Product, 2016 and 2024
    • 5.2. Antibody
      • 5.2.1. Global Antibody market, 2016 – 2024(USD Million)
      • 5.2.2. Global Antibody market by monoclonal antibody, 2016 – 2024(USD Million)
      • 5.2.3. Global Antibody market by Bi-specific Antibody, 2016 – 2024(USD Million)
      • 5.2.4. Global Antibody market by Antibody Drug Conjugates, 2016 – 2024(USD Million)
    • 5.3. Recombinant Protein
      • 5.3.1. Global Recombinant Protein market , 2016 – 2024(USD Million)
    • 5.4. Vaccines
      • 5.4.1. Global Vaccines market , 2016 – 2024(USD Million)
    • 5.5. Others
      • 5.5.1. Global Others market , 2016 – 2024(USD Million)
  • Chapter 6. Global Biologics outsourcing Market – Type Segment Analysis
    • 6.1. Global biologics outsourcing market: Type overview
      • 6.1.1. Global biologics outsourcing market revenue share, by Type, 2016 and 2024
    • 6.2. Kits & Reagents
      • 6.2.1. Global Kits & Reagents market , 2016 – 2024(USD Million)
    • 6.3. Instruments
      • 6.3.1. Global Instruments market , 2016 – 2024(USD Million)
  • Chapter 7. Global Biologics outsourcing Market – Source Segment Analysis
    • 7.1. Global biologics outsourcing market: Source overview
      • 7.1.1. Global biologics outsourcing market revenue share, by Source, 2016 and 2024
    • 7.2. Microbial
      • 7.2.1. Global Microbial source market , 2016 – 2024(USD Million)
    • 7.3. Mammalian
      • 7.3.1. Global Mammalian source market , 2016 – 2024(USD Million)
  • Chapter 8. Global Biologics outsourcing Market – Application Segment Analysis
    • 8.1. Global biologics outsourcing market: Application overview
      • 8.1.1. Global biologics outsourcing market revenue share, by application, 2016 – 2024
    • 8.2. Vaccine & Therapeutics Development
      • 8.2.1. Global biologics outsourcing market for Vaccine & Therapeutics Development, 2016 – 2024 (USD Million)
    • 8.3. Blood & Blood Related Products Testing
      • 8.3.1. Global biologics outsourcing market for Blood & Blood Related Products Testing, 2016 – 2024(USD Million)
    • 8.4. Cellular and Gene Therapy
      • 8.4.1. Global biologics outsourcing market for Cellular and Gene Therapy, 2016 – 2024 (USD Million)
    • 8.5. Tissue and Tissue Related Products Testing
      • 8.5.1. Global biologics outsourcing market for Tissue and Tissue Related Products Testing, 2016 – 2024 (USD Million)
    • 8.6. Stem Cell Research
      • 8.6.1. Global biologics outsourcing market for Stem Cell Research, 2016 – 2024 (USD Million)
  • Chapter 9. Global Biologics outsourcing Market – Regional Segment Analysis
    • 9.1. Global biologics outsourcing market: Regional overview
      • 9.1.1. Global biologics outsourcing market revenue share, by region, 2016 and 2024
    • 9.2. North America
      • 9.2.1. North America biologics outsourcing market revenue, by Product, 2014 – 2024 (USD Million)
      • 9.2.2. North America biologics outsourcing market revenue, by Type, 2014 – 2024 (USD Million)
      • 9.2.3. North America biologics outsourcing market revenue, by Source, 2014 – 2024 (USD Million)
      • 9.2.4. North America biologics outsourcing market revenue, by application, 2014 – 2024 (USD Million)
      • 9.2.5. U.S.
      • 9.2.6. Rest of North America
    • 9.3. Europe
      • 9.3.1. Europe biologics outsourcing market revenue, by Product, 2014 – 2024(USD Million)
      • 9.3.2. Europe biologics outsourcing market revenue, by Type, 2014 – 2024(USD Million)
      • 9.3.3. Europe biologics outsourcing market revenue, by Source, 2014 – 2024(USD Million)
      • 9.3.4. Europe biologics outsourcing market revenue, by application, 2014 – 2024(USD Million)
      • 9.3.5. Germany
      • 9.3.6. UK
      • 9.3.7. France
      • 9.3.8. Italy
      • 9.3.9. Spain
      • 9.3.10. Russia
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific biologics outsourcing market revenue, by Product, 2014 – 2024, (USD Million)
      • 9.4.2. Asia Pacific biologics outsourcing market revenue, by Type, 2014 – 2024, (USD Million)
      • 9.4.3. Asia Pacific biologics outsourcing market revenue, by Source, 2014 – 2024, (USD Million)
      • 9.4.4. Asia Pacific biologics outsourcing market revenue, by application, 2014 – 2024, (USD Million)
      • 9.4.5. China
      • 9.4.6. Japan
      • 9.4.7. India
      • 9.4.8. South East Asia
      • 9.4.9. Rest of Asia Pacific
    • 9.5. Latin America
      • 9.5.1. Latin America biologics outsourcing market revenue, by Product, 2014 – 2024(USD Million)
      • 9.5.2. Latin America biologics outsourcing market revenue, by Type, 2014 – 2024(USD Million)
      • 9.5.3. Latin America biologics outsourcing market revenue, by Source, 2014 – 2024(USD Million)
      • 9.5.4. Latin America biologics outsourcing market revenue, by application, 2014 – 2024(USD Million)
      • 9.5.5. Brazil
      • 9.5.6. Rest of Latin America
    • 9.6. Middle East and Africa
      • 9.6.1. Middle East and Africa biologics outsourcing market revenue, by Product, 2014 – 2024 (USD Million)
      • 9.6.2. Middle East and Africa biologics outsourcing market revenue, by Type, 2014 – 2024 (USD Million)
      • 9.6.3. Middle East and Africa biologics outsourcing market revenue, by Source, 2014 – 2024 (USD Million)
      • 9.6.4. Middle East and Africa biologics outsourcing market revenue, by application, 2014 – 2024 (USD Million)
  • Chapter 10. Company Profile
    • 10.1. BoehringerIngelheim GmbH
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Therapy portfolio
      • 10.1.4. Business strategy
      • 10.1.5. Recent developments
    • 10.2. Catalent, Inc.
      • 10.2.1. Overview
      • 10.2.2. Financials
      • 10.2.3. Therapy portfolio
      • 10.2.4. Business strategy
      • 10.2.5. Recent developments
    • 10.3. GenScript
      • 10.3.1. Overview
      • 10.3.2. Financials
      • 10.3.3. Therapy portfolio
      • 10.3.4. Business strategy
      • 10.3.5. Recent developments
    • 10.4. Innovent Biologics, Inc.
      • 10.4.1. Overview
      • 10.4.2. Financials
      • 10.4.3. Therapy portfolio
      • 10.4.4. Business strategy
      • 10.4.5. Recent developments
    • 10.5. Syngene
      • 10.5.1. Overview
      • 10.5.2. Financials
      • 10.5.3. Therapy portfolio
      • 10.5.4. Business strategy
      • 10.5.5. Recent developments
    • 10.6. Shanghai MedicilonInc.
      • 10.6.1. Overview
      • 10.6.2. Financials
      • 10.6.3. Therapy portfolio
      • 10.6.4. Business strategy
      • 10.6.5. Recent developments
    • 10.7. GL Biochem Corporation Ltd.
      • 10.7.1. Overview
      • 10.7.2. Financials
      • 10.7.3. Therapy portfolio
      • 10.7.4. Business strategy
      • 10.7.5. Recent developments
    • 10.8. GVK Biosciences Private Limited
      • 10.8.1. Overview
      • 10.8.2. Financials
      • 10.8.3. Therapy portfolio
      • 10.8.4. Business strategy
      • 10.8.5. Recent developments
    • 10.9. Horizon Discovery Group plc.
      • 10.9.1. Overview
      • 10.9.2. Financials
      • 10.9.3. Therapy portfolio
      • 10.9.4. Business strategy
      • 10.9.5. Recent developments
    • 10.10. Albany Molecular Research Inc.
      • 10.10.1. Overview
      • 10.10.2. Financials
      • 10.10.3. Therapy portfolio
      • 10.10.4. Business strategy
      • 10.10.5. Recent developments
    • 10.11. Selexis SA
      • 10.11.1. Overview
      • 10.11.2. Financials
      • 10.11.3. Therapy portfolio
      • 10.11.4. Business strategy
      • 10.11.5. Recent developments
    • 10.12. Lonza
      • 10.12.1. Overview
      • 10.12.2. Financials
      • 10.12.3. Therapy portfolio
      • 10.12.4. Business strategy
      • 10.12.5. Recent developments
    • 10.13. Abzena PLC
      • 10.13.1. Overview
      • 10.13.2. Financials
      • 10.13.3. Therapy portfolio
      • 10.13.4. Business strategy
      • 10.13.5. Recent developments
    • 10.14. Adimab LLC.
      • 10.14.1. Overview
      • 10.14.2. Financials
      • 10.14.3. Therapy portfolio
      • 10.14.4. Business strategy
      • 10.14.5. Recent developments
    • 10.15. JHL BIOTECH, INC.
      • 10.15.1. Overview
      • 10.15.2. Financials
      • 10.15.3. Therapy portfolio
      • 10.15.4. Business strategy
      • 10.15.5. Recent developments
    • 10.16. ProteoGenix
      • 10.16.1. Overview
      • 10.16.2. Financials
      • 10.16.3. Therapy portfolio
      • 10.16.4. Business strategy
      • 10.16.5. Recent developments
    • 10.17. Sino Biological Inc.
      • 10.17.1. Overview
      • 10.17.2. Financials
      • 10.17.3. Therapy portfolio
      • 10.17.4. Business strategy
      • 10.17.5. Recent developments
    • 10.18. THE JACKSON LABORATORY
      • 10.18.1. Overview
      • 10.18.2. Financials
      • 10.18.3. Therapy portfolio
      • 10.18.4. Business strategy
      • 10.18.5. Recent developments
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll